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inﬂammatory signal. Second, intact cartilage plugs pre-treated with
mAGC were cultured with synovial ﬂuid from OA patients undergoing
total knee replacement. Sircol and dimethylmethylene blue assays were
used to detect release of ECM components from the plugs, and the
protein and gene expression of inﬂammatory markers and catabolic
enzymes were measured. Finally, an in vivo rat model of OAwas used to
test the ability of mAGC to suppress OA progression.
Results: Here we examine the aggrecan mimic in both ex vivo cartilage
tissue models and an in vivo animal model. Aggrecan-depleted cartilage
plugs had only approximately 30% of the compressive strength of intact
plug. mAGC was able to diffuse into the cartilage tissue and restore the
compressive strength to 90% of the intact healthy cartilage. In addition
to the mechanical effects, depletion of aggrecan resulted in an increase
in catabolic gene expression by the chondrocytes that was further
ampliﬁed with additional inﬂammatory stimuli. Treatment with mAGC
resulted in chondrocyte gene expression of catabolic enzymes at the
same level as healthy intact cartilage, both with and without inﬂam-
matory stimulation over 21 days. Intact cartilage plugs exposed to
osteoarthritic synovial ﬂuid resulted in high degradation of ECM com-
ponents as measured by release into the culture media over an 8-day
period. A single pre-treatment with mAGC decreased this degradation
to levels similar to those in healthy cultured controls. Further, inﬂam-
mation and catabolic enzymatic gene expressionwas lowered in treated
plugs to near healthy levels, even in the presence of the inﬂammatory
and enzyme-rich synovial ﬂuid. The data indicates that by providing
robust protection against degradation and restoring the mechanical
environment, the pro-inﬂammatory signals that cause upregulation of
the degrading enzymes are decreased. In an aggressive rat model,
mAGC was able to keep catabolic enzyme levels closer to healthy levels,
preserve the proteoglycan content of cartilage tissue, and decrease bone
loss as compared to untreated controls.
Conclusions: This study provides the ground-work for development of
an intra-articular therapy that reduces fragmentation of key extrac-
ellular matrix components and restores the mechanical environment of
the cartilage tissue, resulting in decrease in inﬂammation and catabolic
enzyme production. The therapy has the potential to promote a healthy
environment for future tissue regeneration. mAGC is the ﬁrst ther-
apeutic to speciﬁcally target the ECM components of cartilage to offerrobust protection from the numerous destructive factors present in OA.
Further, mAGC is the only therapeutic that targets the mechanical
environment of cartilage tissue. Ongoing work is exploring the efﬁcacy
of mAGC in preventing OA in a spontaneous guinea pig model.
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THE OA TRIAL BANK: META-ANALYSIS OF INDIVIDUAL PATIENT DATA
SHOW THAT PATIENTS WITH SEVERE PAIN OR WITH
INFLAMMATORY SIGNS DETECTED BY ULTRASOUND ESPECIALLY
BENEFIT FROM INTRA-ARTICULAR GLUCOCORTICOIDS FOR KNEE
OR HIP OA
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Purpose: Based on small to moderate effect sizes for the wide range of
symptomatic treatments in osteoarthritis (OA) and on the hetero-
geneity of OA patients, treatment guidelines for OA have stressed the
need for research on clinical predictors of response to treatment. Meta-
analysis to quantify the effect modiﬁed by the predictors using Indi-
vidual Patient Data (IPD) fromworldwide available trials is proposed as
gold standard. The OA Trial Bank initiative therefore evaluated the
efﬁcacy of intra-articular (IA) glucocorticoids for knee and hip OA for
subgroups of patients with severe pain, and inﬂammation on short term
follow-up using IPD from existing trials.
Methods: Study selection
Randomized trials evaluating one or more IA glucocorticoid preparation
in patients with knee or hip OA, published from 1995 up to June 2012
were selected from the existing literature. All IA glucocorticoid prepa-
rations used for treatment of OA of the knee or hip in humans compared
with control treatments, including placebo, IA hyaluronan/hylan and
tidal irrigation were included. The presented preliminary analyses will
include the comparison between IA glucocorticoids and placebo, since
data included in this comparison are complete.
Individual data obtained from original trials included patient charac-
teristics (age, gender, BMI), disease characteristics (duration of com-
plaints, KL score, type of OA, inﬂammatory signs and pain severity) and
outcomes measured (pain severity, physical functioning and patient
global assessment).
Data collection and transfer: Corresponding authors of eligible trials
were approached and asked to cooperate in this project. All data-
deliverers signed a license agreement to guarantee legal issues between
the OA Trial Bank and data-deliverers. All anonymized data were
transferred to a secured database.
Data analyses: All analyses were performed following our published
protocol. The primary outcome was pain severity at short-term follow-
up (up to 4 weeks), converted to a 0 to 100 scale. The subgroup factors
assessed included severe pain (>70 points on a 0-100 scale) and signs of
inﬂammation (dichotomized following study speciﬁc cut-off points).
To assess the subgroup effects, a multilevel regression analysis (random
trial intercept, restricted maximum likelihood algorithm) was applied
to calculate the interaction effects (indicator for difference in response
on treatment for the subgroups). Analyses were adjusted for baseline
pain severity, age, gender and BMI. Interaction effects with P < 0.05
were considered statistically signiﬁcant.
Results: Seven published randomized clinical trials including 309
patients were included in the OA Trial Bank by 1 December 2013
(additional data of 360 patients is afﬁrmed). Of these, four studies with
225 patients (mean age 64.5(SD11.2); 56% male; BMI 28.4(SD4.9);
duration of complaints 86(SD122) months, 60% knees and 40% hips)
compared glucocorticoids with placebo. Severe pain at baseline was
reported by 28.1% of the patients, and inﬂammatory signs (reported by
three studies; two based on ultrasound (synovitis/effusion measured in
millimeters) and in one study measured by evidence of effusion by
physical examination) were present in 51.7% of the subjects.
The overall estimate of the main effect of IA glucocorticoid injection
compared to placebo on short-term pain severity was 22.8 (95%CI13.2-
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at baseline and treatment effect (interaction coefﬁcient 13.6, 95%CI 1.4-
25.8). A non-signiﬁcant overall interaction estimate was found for
inﬂammatory signs 12.5 (95%CI -7.22-32.3). However, a strongly pos-
itive interaction estimate (45.3, 95%CI 24.4-66.1) was found for
inﬂammation and treatment effect when analyzed in the studies where
inﬂammation was measured by ultrasound.
Conclusions: Our results show that patients with severe pain at base-
line do beneﬁt signiﬁcantly more from IA glucocorticoid injections than
those with less severe pain and this could be used as a predictive
measure of response in clinical practice. However inﬂammation deﬁned
by ultrasound provided an even more signiﬁcant measure of a positive
treatment response of IA glucocorticoids in patients with knee or hip
OA. The differences in treatment response at short-term follow-up
between IA glucocorticoid treatment and IA placebo were much larger
when inﬂammatory signs, measured by ultrasound, were present
compared to absence of inﬂammatory signs.
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BONE MARROW LESIONS MAY NOT RESPOND TO ANTI-
INFLAMMATORY TREATMENTS IN KNEE OSTEOARTHRITIS(OA)
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Purpose: Intra-articular steroid therapy to the knee is associated with a
reduction in pain in patients with symptomatic knee OA. The mecha-
nism by which treatment is linked with a reduction in pain is unknown
though thought in part to be related to a reduction in synovitis. Bone
marrow lesions (BMLs) are poorly circumscribed lesions of water signal
on MRI using fat suppressed pulse sequences; while BMLs may be
caused by mechanical stress across the joint, their relation to inﬂam-
mation is unknown though it is possible they may be a candidate target
for steroid therapy as they are linked with knee pain and ﬂuctuate over
time. The aim of this analysis was to determine whether intra-articular
steroid therapy is associated with a change in BMLs.
Methods: Men and women aged 40 years and older with painful knee
OA, and who met American College of Rheumatology criteria for the
disease, were recruited for participation in an ongoing open label
clinical trial of intra-articular steroid therapy. Subjects who took part in
the study had signiﬁcant knee pain and knee OA of grade 2 (Kellgren-
Lawrence) or higher. At baseline they completed also the Knee Injury
and Osteoarthritis Outcome Score (KOOS). They had a Gadolinium(Gd)-
enhanced MRI immediately prior to having an intra-articular steroid
injection with repeat questionnaire and Gd-enhanced MRI scan at the
post-injection visit usually within a 2 week period. Response was
determined using the OARSI responder criteria. Those who responded
were followed up by serial telephone call until their knee pain recurred
or at 6 months at which point a further Gd-enhanced MRI was sched-
uled. The knee images were assessed semi-quantitatively for BML
severity (score 0-45 using the WORMS method) at all three time points
by an experiencedMSK radiologist. Synovial tissue volumewas assessed
using manual segmentation and computer image analysis of the con-
trast enhanced images. We looked at mean change in BML severity
score, between baseline and post-injection visit, and themean change in
BML score between baseline and the ﬁnal scan.We looked also at change
in synovial volume between baseline and the post injection scan.
Results: 100 patients with imaging data were included in this analysis.
Their median age was 62.0 years (SD 10.4 years), and 48 were female.
The median time between baseline and post-injection scan was 8 days
(IQR 7 to 14 days). Among those who responded (67) pain recurred
within 6 months in 46. The median BML score at baseline was 8.0 (IQR
4.0 to 12.0), post-injection visit 8.0 (IQR 4.2 to 12.0) and 7 (IQR 4.0 to
10.9) at ﬁnal visit. The score did not differ between the baseline and
post-injection scan (mean within person difference ¼ 0.05 points; 95%
CI -0.21 to 0.31 points; p ¼ 0.72) however a slight difference was noted
between the baseline and ﬁnal scan (mean within person difference ¼
-0.36 points; 95% CI -0.67 to -0.06 points; p ¼ 0.02). This within-person
difference reﬂects a reduction of 4.6% in the baseline BML score, which,
while statistically signiﬁcant, is a clinically small change. In contrast,
synovial volume shrank between the baseline and post-injection visit
(mean within person difference ¼ -1082mm3; 95% CI -1996 to
-168mm3; p ¼ 0.02). This within-person difference reﬂects a reduction
of 13.2% in the baseline synovitis score.Conclusions: BMLs show little change in response to intra-articular
steroid therapy in patients with symptomatic knee OA, suggesting they
may not respond to anti-inﬂammatory treatments.
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Purpose: Salmon calcitonin (sCT) has been shown to exert beneﬁcial
metabolic actions on cartilage and bone turnover and may therefore be
useful in the management of osteoarthritis (OA). A calcitonin-based oral
treatment for knee OA recently failed to meet the primary endpoint for
efﬁcacy in a two-year placebo-controlled clinical trial, though demon-
strating positive effects on pain and function. The objective of our
project is to synthesize a new polymeric conjugate between hyaluronic
acid (HA) and salmon calcitonin and to evaluate its potential as intra-
articular treatment for OA. The rationale is to retain sCT in the joint
cavity, thus maximizing and prolonging the local activity and avoiding
the side effects related to a systemic administration.
Methods: HA was linked to sCT by means of a spacer having pendant
aldehyde groups for selective conjugation at the N-terminus of the
peptide.
The residual activity of conjugated sCT was investigated in rats by
measuring the plasma calcium level after i.v. injection. Preliminary PK
studies were performed by labeling HA-sCT and sCT with a ﬂuorescent
dye for the detection in blood samples after i.a. injection. In addition,
blood samples were withdrawn at ﬁxed times up to 24 hours and the
total calcium levels were measured using a colorimetric calcium assay.
Unilateral OA was surgically induced in the rabbit knees by anterior
cruciate ligament transection (ACLT). Controls (PBS and HA), sCT and
HA-sCT at 25, 100 and 400 UI, were administered by i.a. injection once a
week at day 10, 17 and 24 post-surgery. The efﬁcacy was evaluated by
macroscopic examination of the treated joint, histopathological
assessment of the synovial membrane and of the femoral condyles. The
histopathological criteria score was based on the evaluation of four
parameters: articular cartilage morphology, subchondral bone mor-
phology, cartilage thickness, and arrangement of chondrocytes.
Results: The new HA-sCT conjugate was synthesized according to a
patented technology that avoids the formation of heterogeneous and
cross-linked products.
The potency of the conjugated sCT was evaluated by i.v. injection,
showing that it maintains a comparable potency with respect to the free
protein and sustains the hypocalcaemic action for a longer time.
Interestingly, after local administration, unlike free sCT, HA-sCT did not
cause a systemic reduction of calcium concentration, suggesting a
negligible extra-articular diffusion of the conjugated peptide.
The PK study with labelled sCTconﬁrmed this encouraging result: while
i.a. injection of HA-sCT led to very low and constant plasma peptide
concentration, the local administration of free sCT resulted in high
ﬂuorescence in plasma, demonstrating a fast clearance of the peptide
